How to buy AVEO Pharmaceuticals stock (AVEO)

AVEO Pharmaceuticals is a business based in the US. AVEO Pharmaceuticals shares (AVEO) are listed on the NASDAQ and all prices are listed in US Dollars. AVEO Pharmaceuticals employs 114 staff and has a trailing 12-month revenue of around $94.3 million.

Our top picks for where to buy AVEO Pharmaceuticals stock

Buy AVEO Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AVEO Pharmaceuticals stock price (NASDAQ: AVEO)

Use our graph to track the performance of AVEO stocks over time.

AVEO Pharmaceuticals shares at a glance

• Key figures

Information last updated 2023-03-12.

52-week range	$0.00 - $0.00
50-day moving average more info button	$14.91
200-day moving average more info button	$9.38
Wall St. target price	$15.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.20

Is it a good time to buy AVEO Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVEO Pharmaceuticals financials

Revenue TTM	$94.3 million
Gross profit TTM	$11.3 million
Return on assets TTM	-14.56%
Return on equity TTM	-72.53%
Profit margin	-30.79%
Book value	$0.83
Market Capitalization more info button	$521.4 million

TTM: trailing 12 months

AVEO Pharmaceuticals share dividends

We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months.

Have AVEO Pharmaceuticals's shares ever split?

AVEO Pharmaceuticals's shares were split on a 1:10 basis on 19 February 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AVEO Pharmaceuticals shares which in turn could have impacted AVEO Pharmaceuticals's share price.

AVEO Pharmaceuticals share price volatility

Over the last 12 months, AVEO Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 0.977. This would suggest that AVEO Pharmaceuticals's shares are less volatile than average (for this exchange).

AVEO Pharmaceuticals overview

AVEO Pharmaceuticals, Inc. , an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc. ; CANbridge Life Sciences, Ltd.

Frequently asked questions

null
What percentage of AVEO Pharmaceuticals is owned by insiders or institutions?
Currently 0.193% of AVEO Pharmaceuticals shares are held by insiders and 34.465% by institutions. How many people work for AVEO Pharmaceuticals?
Latest data suggests 114 work at AVEO Pharmaceuticals. When does the fiscal year end for AVEO Pharmaceuticals?
AVEO Pharmaceuticals's fiscal year ends in December. Where is AVEO Pharmaceuticals based?
AVEO Pharmaceuticals's address is: 30 Winter Street, Boston, MA, United States, 02108 What is AVEO Pharmaceuticals's ISIN number?
AVEO Pharmaceuticals's international securities identification number is: US0535883070 What is AVEO Pharmaceuticals's CUSIP number?
AVEO Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 053588307